Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

The Lancet Oncology

Volumn 17, Issue 11, 2016, Pages 1579-1589

  Ledermann, Jonathan A ^a   Harter, Philipp ^b   Gourley, Charlie ^c   Friedlander, Michael ^d   Vergote, Ignace ^e   Rustin, Gordon ^f   Scott, Clare ^g   Meier, Werner ^h   Shapira Frommer, Ronnie ⁱ   Safra, Tamar ^j   Matei, Daniela ^k   Fielding, Anitra ^l   Spencer, Stuart ^l   Rowe, Philip ^l   Lowe, Elizabeth ^l   Hodgson, Darren ^l   Sovak, Mika A ^l   Matulonis, Ursula ^m  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KLINIKEN ESSEN MITTE   (Germany)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f MOUNT VERNON HOSPITAL   (United Kingdom)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h Children s Hospital   (Germany)

ⁱ SHEBA MEDICAL CENTER   (Israel)

^j TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^k NORTHWESTERN UNIVERSITY   (United States)

^l ASTRAZENECA   (United Kingdom)

^m DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; OLAPARIB; PLACEBO; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; BRONCHIECTASIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; FOLLOW UP; HEART FAILURE; HEART PALPITATION; HERPES ZOSTER; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUTH SQUAMOUS CELL CARCINOMA; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PANCYTOPENIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPTIC SHOCK; THROMBOCYTOPENIA; VOMITING; AGED; CLINICAL TRIAL; CYSTADENOCARCINOMA, SEROUS; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; OVARIAN NEOPLASMS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; CYSTADENOCARCINOMA, SEROUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 85015347376     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30376-X     Document Type: Article

References (23)

1. 1 Ferlay, J, Steliarova-Foucher, E, Lortet-Tieulent, J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49 (2013), 1374–1403.
2. 2 WHO. GLOBOCAN statistics. http://globocan.iarc.fr/, 2012 (accessed Aug 26, 2016).
3. 3 Ledermann, JA, Raja, FA, Fotopoulou, C, Gonzalez-Martin, A, Colombo, N, Sessa, C, Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:suppl 6 (2013), vi24–vi32.
4. 4 Kyrgiou, M, Salanti, G, Pavlidis, N, Paraskevaidis, E, Ioannidis, JP, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst 98 (2006), 1655–1663.
5. 5 de Angelis, R, Sant, M, Coleman, MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 15 (2014), 23–34.
6. 6 Ledermann, J, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 (2012), 1382–1392.
7. 7 Ledermann, J, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15 (2014), 852–861.
8. 8 Kaufman, B, Shapira-Frommer, R, Schmutzler, RK, et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol 33 (2015), 244–250.
9. 9 Murai, J, Huang, SY, Das, BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72 (2012), 5588–5599.
10. 10 Farmer, H, McCabe, N, Lord, CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
11. 11 Bryant, HE, Schultz, N, Thomas, HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005), 913–917.
12. 12 EMA. Lynparza recommended for approval in ovarian cancer. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10/news_detail_002196.jsp&mid=WC0b01ac058004d5c1, 2014 (accessed Aug 26, 2016).
13. 13 FDA. Olaparib. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427598.htm, 2014 (accessed Aug 26, 2016).
14. 14 AstraZeneca. Global Policy: Bioethics. https://www.astrazeneca.com/sustainability/responsible-research.html, 2015 (accessed Aug 26, 2016).
15. 15 Anderson, PK, Hansen, MG, Klein, JP, Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal 10 (2004), 335–350.
16. 16 Dougherty B, Lai Z, Ledermann JA, et al. Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition. Annual Meeting of the American Association for Cancer Research; Philadelphia, PA, USA; April 18–22, 2015. abst 611.
17. 17 Grambsch, P, Therneau, T, Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994), 515–526.
18. 18 Lheureux, S, Ledermann, JA, Runswick, S, et al. Genomic characterization of long-term responders to olaparib. Proc Am Soc Clin Oncol, 33(suppl), 2015 (abst) 5566.
19. 19 McCabe, N, Turner, NC, Lord, CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66 (2006), 8109–8115.
20. 20 Press, JZ, De Luca, A, Boyd, N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer, 8, 2008, 17.
21. 21 Hodgson, DR, Dougherty, B, Lai, Z, et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Eur J Cancer, 51(suppl S3), 2015 abst 435.
22. 22 Matulonis, UA, Oza, AM, Ho, TW, Ledermann, JA, Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer 121 (2015), 1737–1746.
23. 23 Matulonis, U, Harter, P, Gourley, C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: overall survival adjusted for post-progression PARP inhibitor therapy. Cancer 122 (2016), 1844–1852.